1. Home
  2. OPRT vs IKT Comparison

OPRT vs IKT Comparison

Compare OPRT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oportun Financial Corporation

OPRT

Oportun Financial Corporation

HOLD

Current Price

$8.09

Market Cap

275.7M

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.30

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPRT
IKT
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.7M
220.5M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
OPRT
IKT
Price
$8.09
$2.30
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$7.00
$5.00
AVG Volume (30 Days)
354.4K
360.8K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
127.18
57.76
EPS
0.22
N/A
Revenue
$956,685,000.00
N/A
Revenue This Year
$32.79
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$36.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.03
$1.33
52 Week High
$8.30
$2.61

Technical Indicators

Market Signals
Indicator
OPRT
IKT
Relative Strength Index (RSI) 63.66 46.52
Support Level $7.12 $2.29
Resistance Level $8.23 $2.56
Average True Range (ATR) 0.31 0.10
MACD -0.00 -0.02
Stochastic Oscillator 97.32 20.28

Price Performance

Historical Comparison
OPRT
IKT

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: